The best news from Turkmenistan on business and economy
Provided by AGP
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The hemophilia clinical trial analysis report delivers important insights into ongoing research of 55+ pipeline hemophilia drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
New York, USA, May 05, 2026 (GLOBE NEWSWIRE) -- Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The hemophilia clinical trial analysis report delivers important insights into ongoing research of 55+ pipeline hemophilia drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
DelveInsight’s 'Hemophilia Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for hemophilia across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the hemophilia domain.
Hemophilia Clinical Trial Analysis Summary
- DelveInsight’s hemophilia pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline hemophilia drugs.
- Key hemophilia companies, such as Novo Nordisk A/S, Suzhou Alphamab, Roche, Chugai Pharmaceutical Co., Ltd., Be Biopharma, Regeneron Pharmaceuticals, Intellia Therapeutics, Equilibra Bioscience, TiumBio, Metagenomi Therapeutics, Gritgen Therapeutics, Cabalettabio, Link Bio, GCBiopharma, Bayer, Jiangsu Gensciences lnc., Belief Biomed, Sernova, and others, are evaluating new hemophilia drugs to improve the treatment landscape.
- Promising pipeline hemophilia therapies, such as Denecimig, KN057, NXT007, BE-101, REGV131-LNP1265, SR604, TU7710, MGX 001, GS1191-0445, FVIII-CAART, LB02, MG1113A, BAY2599023, SS109, BBM H803, Haemophilia A allogenic cell therapy, and others, are in different phases of hemophilia clinical trials.
- Approximately 10+ hemophilia drugs are in the late and mid stages of development.
- Notable MoAs in hemophilia clinical trials include FVIII mimetic, Immunomodulators, Anti-FIXa/FX, Factor IX replacement, Factor IX replacement, Activated protein C inhibition, Blood coagulation factor modulator, Factor VII replacement, and others.
Request a sample and discover the recent advances in hemophilia drug development @ https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight
What is Hemophilia?
Hemophilia is a rare inherited bleeding disorder in which the blood does not clot properly due to a deficiency or absence of specific clotting factors, most commonly factor VIII (Hemophilia A) or factor IX (Hemophilia B). Because of this defect, individuals with hemophilia may experience prolonged bleeding after injuries, surgeries, or even spontaneous internal bleeding, particularly into joints and muscles. The condition is typically caused by genetic mutations on the X chromosome, which is why it predominantly affects males, while females are usually carriers. Severity can vary depending on the level of clotting factor present, ranging from mild cases with bleeding only after major trauma to severe forms characterized by frequent spontaneous bleeding episodes. Modern treatments, including clotting factor replacement therapies and newer gene therapies, have significantly improved disease management and quality of life for patients.
Find out more about hemophilia drug development @ Hemophilia Treatment
A snapshot of the Pipeline Hemophilia Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Denecimig | Novo Nordisk A/S | Preregistration | FVIII mimetic | Subcutaneous |
| KN057 | Suzhou Alphamab | III | Immunomodulators | Subcutaneous |
| NXT007 | Roche/Chugai Pharmaceutical Co., Ltd. | III | Anti-FIXa/FX | Subcutaneous |
| BE-101 | Be Biopharma | I/II | Factor IX replacement | IV infusion |
| REGV131-LNP1265 | Regeneron Pharmaceuticals/ Intellia Therapeutics | I/II | Factor IX replacement | IV infusion |
| SR604 | Equilibra Bioscience | I | Activated protein C inhibition | Subcutaneous |
| TU7710 | TiumBio | I | Blood coagulation factor modulator | Intravenous |
| MGX 001 | Metagenomi Therapeutics | Preclinical | Factor VII replacement | Intravenous |
Learn more about the emerging hemophilia therapies @ Hemophilia Clinical Trials
According to Stuti Mahajan, consulting manager at DelveInsight, the market is being driven by the growing uptake of advanced treatment options, particularly long-acting factor therapies and emerging gene therapies, which are helping patients manage the condition more effectively with fewer interventions. As these more convenient and potentially transformative therapies gain traction, they are steadily shaping growth in the hemophilia treatment landscape.
Recent Developments in Hemophilia Treatment Space
- In March 2026, Metagenomi Inc. provided an update on its MGX-001 program, announcing the successful completion of a pre-IND meeting and reaffirming its timeline to advance the global clinical program, with an IND submission planned for Q4 2026 and initiation of clinical trials in 2027, subject to regulatory clearance.
- In February 2026, Chugai Pharmaceutical Co., Ltd. announced that the data from Part C of the Phase I/II NXTAGE study, the first clinical data evaluating NXT007 in people switching from emicizumab without a washout period, were presented at the 2026 European Association for Haemophilia and Allied Disorders (EAHAD) Congress held in Ireland.
- In November 2025, Metagenomi Inc. announced new preclinical data for its hemophilia A gene-editing therapy MGX-001, demonstrating curative levels of factor VIII (FVIII) activity in non-human primates. The results support advancement of the program into clinical development. The company plans to conduct regulatory interactions and submit IND/CTA applications in 2026 to initiate first-in-human clinical trials.
- In September 2025, Novo Nordisk A/S submitted a Biologics License Application to the US FDA seeking approval for Mim8 (denecimig), an investigational subcutaneous prophylactic therapy for Hemophilia A with or without inhibitors. The application is supported by Phase III data showing a significant reduction in bleeding episodes, and the therapy is designed to offer flexible weekly to monthly dosing options.
- In July 2025, Be Biopharma, Inc announced the first participant was treated with BE-101 in the BeCoMe-9 Phase I/II clinical trial designed to assess the safety and preliminary efficacy of BE-101 in participants with moderately severe to severe hemophilia B.
- In May 2024, FDA granted Fast Track Designation (FTD) to SR604 for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with severe hemophilia A and severe hemophilia B with or without inhibitors.
- In December 2024, TiumBio announced the successful completion of its Phase Ia clinical trial of TU7710, a long-acting recombinant activated factor VII, along with positive Phase Ia results.
Scope of the Hemophilia Pipeline Report
- Coverage: Global
- Hemophilia Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Hemophilia Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Hemophilia Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Hemophilia Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- Hemophilia Therapeutics Assessment By Mechanism of Action: FVIII mimetic, Immunomodulators, Anti-FIXa/FX, Factor IX replacement, Factor IX replacement, Activated protein C inhibition, Blood coagulation factor modulator, Factor VII replacement, and others
- Key Hemophilia Companies: Novo Nordisk A/S, Suzhou Alphamab, Roche, Chugai Pharmaceutical Co., Ltd., Be Biopharma, Regeneron Pharmaceuticals, Intellia Therapeutics, Equilibra Bioscience, TiumBio, Metagenomi Therapeutics, Gritgen Therapeutics, Cabalettabio, Link Bio, GCBiopharma, Bayer, Jiangsu Gensciences lnc., Belief Biomed, Sernova and others
- Key Hemophilia Pipeline Therapies: Denecimig, KN057, NXT007, BE-101, REGV131-LNP1265, SR604, TU7710, MGX 001, GS1191-0445, FVIII-CAART, LB02, MG1113A, BAY2599023, SS109, BBM H803, Haemophilia A allogenic cell therapy and others.
Dive deep into rich insights for new hemophilia treatments, visit @ Hemophilia Drugs
Table of Contents
| 1. | Hemophilia Pipeline Report Introduction |
| 2. | Hemophilia Pipeline Report Executive Summary |
| 3. | Hemophilia Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Hemophilia Clinical Trial Therapeutics |
| 6. | Hemophilia Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Hemophilia Pipeline: Late-Stage Products (Phase III) |
| 8. | Hemophilia Pipeline: Mid-Stage Products (Phase II) |
| 9. | Hemophilia Pipeline: Early-Stage Products (Phase I) |
| 10. | Hemophilia Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Hemophilia Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Hemophilia Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the hemophilia cure research, reach out @ Medication for Hemophilia Treatment
Related Reports
Hemophilia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hemophilia companies, including Roche (Genentech), Takeda, Novo Nordisk, Pfizer, CSL Behring, Bayer, Sanofi, BioMarin Pharmaceutical, and others.
Hemophilia A Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key hemophilia A companies, including BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.
Hemophilia B Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia B companies, including Centessa Pharmaceuticals, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Spark Therapeutics, Be Biopharma, Equilibra Bioscience, Regeneron Pharmaceuticals, Intellia Therapeutics, Novo Nordisk, and others.
Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, and others.
Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sickle cell disease companies, including Vertex Pharmaceuticals, CRISPR Therapeutics, Bluebird Bio, Global Blood Therapeutics, Pfizer, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
